The biological process of lysine-tRNA charging is therapeutically targetable in liver cancer.

Ruyi ZhangLisanne NoordamXumin OuBuyun MaYunlong LiPronay DasShaojun ShiJiaye LiuLing WangPengfei LiMonique M A VerstegenD Srinivasa ReddyLuc J W van der LaanMaikel P PeppelenboschJaap KwekkeboomRon SmitsMaikel P Peppelenbosch

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

The biological process of charging tRNA-Lys-CUU with lysine sustains liver cancer cell growth and migration, and is clinically relevant in HCC patients. This process can be therapeutically targeted and represents an unexplored territory for developing novel treatment strategies against liver cancer.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
amino acid
patient reported outcomes